Clinical Trial Update: Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of sintilimab, bevacizumab, and selective internal radiation therapy (SIRT) for non-resectable hepatocellula…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: RECRUITING